Daxor (DXR) vs Nephros (NEPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Daxor (DXR) has outperformed Nephros (NEPH) over the past year, losing 20.0% versus a loss of 36.2%. Over five years, DXR leads with a -7.0% price change compared with -57.6% for NEPH. Daxor is the larger company by market cap ($61.8 million vs $37.7 million), about 1.6 times the size.
On valuation, Daxor trades at a lower trailing P/E (9.6x vs 23.2x for Nephros).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | NEPH |
|---|---|---|
| Share price | $10.58 | $3.48 |
| Market cap | $61.77M | $37.74M |
| 1-day change | +1.15% | +5.62% |
| YTD return | -29.08% | -32.58% |
| 1-year return | -20.03% | -36.24% |
| 5-year return | -7.02% | -57.60% |
| P/E ratio (TTM) | 9.62 | 23.17 |
| Forward P/E | — | 16.55 |
| EPS (TTM) | $1.10 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.76 | $6.42 |
| 52-week low | $8.56 | $2.66 |
| Distance from 52-week high | -28.32% | -45.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +89.04% | +79.86% |
| Average volume | 17.27K | 27.59K |
| Shares outstanding | 5.84M | 10.86M |
| Employees | — | 36 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXR has outperformed NEPH by 16.2 percentage points over the past year.
- Nephros trades at a higher earnings multiple (23.2x vs 9.6x trailing P/E).
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
DXR vs NEPH FAQ
Which is bigger, Daxor or Nephros?
Daxor (DXR) is larger, with a market capitalization of $61.77M compared with $37.74M for Nephros (NEPH).
Which stock has performed better over the past year, DXR or NEPH?
DXR returned -20.03% over the past 12 months, compared with -36.24% for NEPH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXR or NEPH?
DXR has the lower trailing P/E at 9.6, versus 23.2 for NEPH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Daxor and Nephros in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.